Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Allergan Aesthetics, an AbbVie company, received European Commission approval for Boey, the first rapid-onset, short-duration botulinum neurotoxin serotype E for the treatment of glabellar lines. Clinical data indicates results may be seen as early as eight hours after treatment and typically wear off within two to three weeks, providing a temporary option for patients interested in trying facial injectables.
Key figures
- Drug Name
- Boey (trenibotulinumtoxinE)
- Phase Of Trial
- Phase 3
- Dose
- 700 U
- Duration
- 2 to 3 weeks
- Onset time
- as early as 8 hours
- Trial patients
- 725
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.